Skip to main content

High Cholesterol - Familial Homozygous News

Related terms: Familial Hypercholesterolemia, Homozygous, Homozygous Familial Hypercholesterolemia, Homozygous FH, Hypercholesterolemia, Familial Homozygous

Combination Lipid-Lowering Therapy Linked to Greater Drop in LDL-C

FRIDAY, March 28, 2025 – Combination lipid-lowering therapy (LLT) is associated with a greater reduction in low-density lipoprotein cholesterol (LDL-C) compared with statin monotherapy, according to...

Olpasiran Leads to Significant Reduction in Oxidized Phospholipids

FRIDAY, Feb. 21, 2025 – Olpasiran, a small interfering RNA, which blocks lipoprotein(a) (Lp[a]) production, leads to a significant and sustained reduction in oxidized phospholipids (OxPL) on...

Cholesterol Changes in Seniors Linked to Brain Health

THURSDAY, Jan. 30, 2025 – Seniors whose cholesterol levels spike and plummet year-to-year could be at increased risk of dementia and failing brain health, a new study suggests. Those whose...

Prevalence of High Total Cholesterol 11.3 Percent in U.S. Adults

WEDNESDAY, Nov. 20, 2024 – The prevalence of high total cholesterol was 11.3 percent among U.S. adults in August 2021 to August 2023, according to a November data brief published by the National...

About 1 in 10 U.S. Adults Have High Cholesterol

WEDNESDAY, Nov. 20, 2024 – Nearly 1 in every 10 American adults is living with high levels of cholesterol in their arteries, according to the latest report from the U.S. Centers for Disease Control...

Fish Oil Supplements Counteract Genetic Predisposition to High Cholesterol

WEDNESDAY, Aug. 14, 2024 – Fish oil seems to counteract genetic predisposition to high cholesterol, according to a study published online July 15 in the American Journal of Clinical Nutrition. ...

Fish Oil Might Help Keep Cholesterol in Check

THURSDAY, Aug. 8, 2024 – People with a genetic predisposition for high cholesterol can lower their levels by taking fish oil supplements, a new study shows. The results indicate that lifestyle can...

Plozasiran Reduces Triglyceride Levels in Mixed Hyperlipidemia

MONDAY, June 3, 2024 – For individuals with mixed hyperlipidemia, plozasiran reduces triglyceride levels at 24 weeks, according to a study published online May 28 in the New England Journal of...

FDA Approves First-in-class Evkeeza (evinacumab-dgnb) for Young Children with Ultra-Rare Form of High Cholesterol

TARRYTOWN, N.Y., March 22, 2023 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has extended the approval of Evkeeza...

FDA Medwatch Alert: FDA Requests Removal of Strongest Warning Against Using Cholesterol-Lowering Statins During Pregnancy; Still Advises Most Pregnant Patients Should Stop Taking Statins

What safety information is FDA announcing? The U.S. Food and Drug Administration (FDA) is requesting removal of its strongest warning against using cholesterol-lowering statin medicines in pregnant...

FDA Approves Roszet (rosuvastatin and ezetimibe) to Reduce LDL-C in Hyperlipidemia and Homozygous Familial Hypercholesterolemia

Morristown, N.J. March 31, 2021 – Althera Pharmaceuticals, a company focused on heart health, today announced the FDA approval of Roszet (rosuvastatin and ezetimibe) tablets, as an adjunct to diet,...

FDA Approves Evkeeza (evinacumab-dgnb) for Patients with Homozygous Familial Hypercholesterolemia

TARRYTOWN, N.Y., Feb. 11, 2021 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) approved Evkeeza (evinacumab-dgnb) as an...

FDA Approves Amgen's Repatha (evolocumab) to Prevent Heart Attack and Stroke

THOUSAND OAKS, Calif., Dec. 1, 2017 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that following priority review of its supplemental Biologics License Application, the U.S. Food and Drug...

FDA Approves Repatha (evolocumab) to Treat Certain Patients with High Cholesterol

August 27, 2015 – The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under...

FDA Approves Merck’s Liptruzet (ezetimibe and atorvastatin), a New Product That Can Help Lower LDL Cholesterol

Friday, May 3, 2013 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Liptruzet (ezetimibe and atorvastatin)...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

High Cholesterol

Related drug support groups

atorvastatin, Lipitor, simvastatin, Repatha, Crestor, rosuvastatin